PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company that is focused on finding novel therapies for cardiovascular and cardiopulmonary diseases. Its pipeline includes bentracimab, a reversal agent for ticagrelor, PB1046 for pulmonary arterial hypertension and hospitalized COVID-19 patients and PB6440 for resistant hypertension. The company utilizes its proprietary elastin-like polypeptide technology platform to develop therapies with better pharmacokinetics and less-frequent dosing, which leads to both internal and partnership drug-development opportunities.